

FOUNDAYO - (EQ 0.8MG BASE, EQ 2.5MG BASE, EQ 5.5MG BASE, EQ 9MG BASE, EQ 14.5MG BASE, EQ 17.2MG BASE; TABLET)

Generic Name	ORFORGLIPRON CALCIUM	Innovator	None
Dosage	EQ 0.8MG BASE, EQ 2.5MG BASE, EQ 5.5MG BASE, EQ 9MG BASE, EQ 14.5MG BASE, EQ 17.2MG BASE; TABLET	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events



Please Contact contact@researchdelta.com to get Detailed Information.